Koers Immunoprecise Antibodies Ltd Toronto S.E.
Aandelen
TQY
CA87588T2020
Farmaceutische producten
Omzet 2024 * | 24,59 mln. 18,04 mln. 16,66 mln. | Omzet 2025 * | 29,82 mln. 21,87 mln. 20,21 mln. | Marktkapitalisatie | 43,1 mln. 31,62 mln. 29,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -8,8 mln. -8,13 mln. | Nettowinst (verlies) 2025 * | -9 mln. -6,6 mln. -6,1 mln. | EV/omzet 2024 * | 1,75 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,45 x |
K/w-verhouding 2024 * |
-3,42
x | K/w-verhouding 2025 * |
-4,63
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,41% |
Recentste transcriptie over Immunoprecise Antibodies Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,26% | 89,46 mld. | |
+2,76% | 40,74 mld. | |
-12,32% | 33,03 mld. | |
+53,93% | 24,68 mld. | |
-17,39% | 15,12 mld. | |
-9,14% | 12,81 mld. | |
-10,48% | 11,79 mld. | |
-42,45% | 11,64 mld. | |
+7,19% | 8,9 mld. |